IS LONG-TERM LOW-MOLECULAR-WEIGHT HEPARIN STILL ACCEPTABLE TO PALLIATIVE CARE PATIENTS IN THE TREATMENT OF CANCER-ASSOCIATED THROMBOSIS? A QUALITATIVE STUDY REVISITED
IS LONG-TERM LOW-MOLECULAR-WEIGHT HEPARIN STILL ACCEPTABLE TO PALLIATIVE CARE PATIENTS IN THE TREATMENT OF CANCER-ASSOCIATED THROMBOSIS? A QUALITATIVE STUDY REVISITED